Clinical Trial Update: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TQB2450 with Anlotinib capsules versus Paclitaxel weekly for relapsed platinum-resistant ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Anlotinib hydrochloride capsules (anlotinib hydrochloride)
• PACLITAXEL (PACLITAXEL)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Recurrent Platinum-resistant Ovarian Cancer | Phase 3 | Status: UNKNOWN